| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 178 | 198 | 193 | 203 | 205 | 225 | 225 | 210 | 146 | 291 | 279 | 294 | 346 | 308 | 296 | 312 | 283 | 305 | 292 | 284 | 280 | 310 | 293 | 334 | 316 | 353 | 325 | 352 |
| Expenses | 132 | 146 | 142 | 145 | 156 | 161 | 159 | 173 | 131 | 198 | 188 | 195 | 224 | 212 | 218 | 231 | 211 | 221 | 215 | 212 | 214 | 234 | 226 | 251 | 235 | 260 | 251 | 283 |
| EBITDA | 46 | 53 | 51 | 58 | 49 | 64 | 66 | 37 | 15 | 94 | 90 | 99 | 122 | 96 | 78 | 81 | 72 | 83 | 77 | 72 | 66 | 76 | 67 | 83 | 81 | 93 | 75 | 69 |
| Operating Profit % | 25 % | 25 % | 26 % | 28 % | 24 % | 28 % | 29 % | 16 % | 8 % | 32 % | 32 % | 33 % | 31 % | 30 % | 26 % | 24 % | 24 % | 26 % | 25 % | 25 % | 23 % | 24 % | 22 % | 24 % | 25 % | 26 % | 22 % | 18 % |
| Depreciation | 5 | 5 | 5 | 5 | 8 | 9 | 11 | 11 | 10 | 11 | 11 | 14 | 13 | 15 | 17 | 18 | 21 | 22 | 23 | 23 | 21 | 22 | 25 | 26 | 26 | 27 | 28 | 29 |
| Interest | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 3 | 5 | 6 | 8 | 7 | 6 | 6 | 6 | 6 | 5 | 6 | 5 | 5 | 5 | 5 |
| Profit Before Tax | 42 | 48 | 46 | 52 | 39 | 53 | 53 | 23 | 4 | 81 | 78 | 82 | 103 | 78 | 56 | 57 | 43 | 55 | 48 | 42 | 39 | 48 | 37 | 51 | 51 | 61 | 42 | 36 |
| Tax | 14 | 18 | 14 | 17 | 12 | 10 | 11 | 8 | 1 | 21 | 19 | 20 | 28 | 19 | 15 | 16 | 9 | 14 | 12 | 8 | 10 | 13 | 10 | 14 | 13 | 15 | 11 | 7 |
| Net Profit | 27 | 30 | 31 | 35 | 27 | 43 | 42 | 16 | 3 | 61 | 59 | 61 | 75 | 58 | 41 | 40 | 34 | 41 | 36 | 34 | 29 | 36 | 27 | 37 | 38 | 47 | 32 | 29 |
| EPS in ₹ | 4.83 | 6.14 | 6.26 | 6.87 | 5.34 | 8.57 | 8.38 | 3.09 | 0.57 | 11.88 | 11.50 | 12.05 | 14.65 | 11.39 | 8.02 | 7.81 | 6.53 | 7.88 | 6.99 | 6.51 | 5.62 | 6.92 | 5.30 | 7.11 | 7.41 | 9.08 | 6.12 | 5.69 |
Metropolis Healthcare
Metropolis Healthcare
2,014.00
-26.60
(-1.30%)
Market Cap
10,432.90 Cr
EPS
28.29
PE Ratio
75.43
Dividend Yield
0.00 %
Industry
Healthcare Services52 Week High
2,318.30
52 Week Low
1,315.00
PB Ratio
7.97
Debt to Equity
0.17
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
3,208.60 | #1 26,880.21 | 50.49 | #1 2,554.80 | 11.28 | #1 492 | 24.30 | 61.01 | |
1,075.00 | 11,038.86 | 73.97 | 681.39 | 20.11 | 152 | 22.54 | 57.98 | |
2,014.00 | #3 10,432.90 | #9 75.43 | #2 1,346.30 | #10 4.59 | #3 146 | #10 -20.00 | 64.27 | |
1,312.80 | 6,957.11 | 67.38 | 702.20 | 20.80 | 91 | 60.25 | 74.19 | |
845.25 | 2,729.29 | 35.23 | 717.16 | 25.65 | 81 | 10.70 | 62.39 | |
296.70 | 1,545.24 | 48.45 | 252.09 | 14.77 | 31 | 14.29 | 30.43 | |
1,576.95 | 1,353.49 | 27.91 | 96.47 | 25.47 | 49 | -9.09 | 51.61 | |
283.30 | 901.19 | #1 9.74 | 1,110.95 | 35.04 | -197 | -18.52 | 52.13 | |
259.35 | 506.87 | 28.00 | 147.04 | #1 248.07 | 18 | #1 175.00 | 52.73 | |
191.00 | 133.02 | 85.82 | 41.78 | 6.34 | 1 | 28.57 | 58.38 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
4.59 %
Net Income Growth
-10.39 %
Cash Flow Change
-0.50 %
ROE
-19.21 %
ROCE
-13.10 %
EBITDA Margin (Avg.)
-8.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Fixed Assets | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | 1,447 |
| Current Assets | 300 | 305 | 397 | 609 | 393 | 303 | 316 | 346 |
| Capital Work in Progress | 0 | 6 | 3 | 0 | 6 | 20 | 0 | 0 |
| Investments | 102 | 33 | 14 | 10 | 16 | 15 | 55 | 71 |
| Other Assets | 221 | 301 | 439 | 651 | 450 | 347 | 323 | 349 |
| Total Liabilities | 530 | 553 | 752 | 1,004 | 1,530 | 1,502 | 1,555 | 1,867 |
| Current Liabilities | 91 | 125 | 170 | 204 | 302 | 265 | 246 | 294 |
| Non Current Liabilities | 11 | 8 | 58 | 92 | 341 | 246 | 210 | 238 |
| Total Equity | 429 | 420 | 525 | 708 | 888 | 991 | 1,099 | 1,335 |
| Reserve & Surplus | 405 | 409 | 513 | 696 | 876 | 978 | 1,078 | 1,313 |
| Share Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 | -23 |
| Investing Activities | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | -199 |
| Operating Activities | 70 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | 263 |
| Financing Activities | -10 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | -87 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 50.38 % | 50.37 % | 50.33 % | 49.50 % | 49.79 % | 49.79 % | 49.76 % | 49.76 % | 49.75 % | 49.75 % | 49.74 % | 49.74 % | 49.67 % | 49.62 % | 49.43 % | 49.40 % | 48.90 % | 48.89 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 24.29 % | 0.00 % | 18.90 % | 18.25 % | 18.56 % | 16.73 % | 15.29 % | 12.83 % |
| DIIs | 15.34 % | 14.22 % | 11.77 % | 10.63 % | 15.32 % | 13.85 % | 11.88 % | 13.30 % | 13.64 % | 14.47 % | 16.86 % | 20.28 % | 24.86 % | 27.43 % | 28.02 % | 30.00 % | 30.30 % | 32.40 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.95 % | 3.98 % | 4.24 % | 6.50 % | 9.14 % | 9.26 % | 9.45 % | 9.73 % | 8.53 % | 8.15 % | 7.78 % | 6.63 % | 5.24 % | 4.07 % | 3.54 % | 3.34 % | 3.84 % | 4.16 % |
| Others | 30.33 % | 31.43 % | 33.66 % | 33.37 % | 25.75 % | 27.10 % | 28.91 % | 27.21 % | 28.08 % | 27.62 % | 1.32 % | 23.35 % | 1.33 % | 0.63 % | 0.45 % | 0.53 % | 1.68 % | 1.72 % |
| No of Share Holders | 30,679 | 33,527 | 43,552 | 64,168 | 79,895 | 86,404 | 90,090 | 91,452 | 84,269 | 89,692 | 86,249 | 79,878 | 68,283 | 58,108 | 51,852 | 48,572 | 49,293 | 50,015 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 13.26 | 8 | 8 | 8 | 8 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.03 | 0.36 | 0.39 | 0.67 | 0.46 | 0.26 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Aug 2025 |  Annual General Meeting | NA | 13 Aug 2025 | 1,938.80 | 2,040.60 |
| 07 Aug 2025 |  Quarterly Result Announcement | NA | 07 Aug 2025 | 2,019.00 | 2,040.60 |
| 13 May 2025 | Quarterly Result Announcement | NA | 13 May 2025 | 1,694.80 | 1,712.30 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 1,708.90 | 1,757.75 |
| 08 Nov 2024 | Quarterly Result Announcement | NA | 08 Nov 2024 | 2,119.10 | 2,112.60 |
| 21 Aug 2024 | Annual General Meeting | NA | 21 Aug 2024 | 2,098.30 | 2,091.55 |
| 17 Nov 2023 |  Dividend | ₹ 4.00 /share | 17 Nov 2023 | 1,472.25 | 1,606.85 |
| 23 Feb 2023 | Dividend | ₹ 8.00 /share | 23 Feb 2023 | 1,289.35 | 1,348.60 |
| 22 Feb 2022 | Dividend | ₹ 8.00 /share | 21 Feb 2022 | 2,459.95 | 1,976.10 |
| 19 Feb 2021 | Dividend | ₹ 8.00 /share | 17 Feb 2021 | 2,163.55 | 2,011.85 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 days ago
3 days agoBoard Meeting Intimation for Considering And Approving The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 20254 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationJul 23, 2025
Jul 23, 2025Letter To Shareholders Containing Weblink Of 25Th Annual General Meeting And Annual Report For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 25Th Annual General Meeting For The Financial Year 2024-25Jul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Disclosure Under Regulation 30 Of Listing RegulationsJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 11, 2025
Jul 11, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2025
Jul 08, 2025Business Update For Q1FY26Jul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 04, 2025
Jul 04, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 02, 2025
Jul 02, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jul 01, 2025
Jul 01, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 18, 2025
Jun 18, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 18 2025Jun 18, 2025
Jun 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 17, 2025
Jun 17, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 16, 2025
Jun 16, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 13, 2025
Jun 13, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Jun 03, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 03, 2025
Jun 03, 2025Intimation Of Cancellation Of Analyst / Institutional Investor Meeting Scheduled On June 03 2025Jun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMay 24, 2025
May 24, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 19, 2025
May 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2025
May 13, 2025Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Financial Year Ended March 31 2025May 13, 2025
May 13, 2025Board Meeting Outcome for For The Meeting Held Today (May 13 2025)May 13, 2025
May 13, 2025Board Meeting Outcome for For The Meeting Held Today (May 13 2025)May 13, 2025
May 13, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)May 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 08, 2025
May 08, 2025Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 16, 2025
Apr 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Apr 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2025
Apr 07, 2025Technical Indicators
RSI(14)
Neutral 64.27
ATR(14)
Less Volatile 62.80
STOCH(9,6)
Neutral 59.88
STOCH RSI(14)
Neutral 44.23
MACD(12,26)
Bullish 0.39
ADX(14)
Strong Trend 45.13
UO(9)
Bearish 55.50
ROC(12)
Uptrend And Accelerating 4.01
WillR(14)
Overbought -9.96
Mutual Fund Holdings
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Franklin India Opportunities Direct Fund-Growth 
Kotak Small Cap Fund Direct-Growth 
Sundaram Business Cycle Fund Direct - Growth 
Tata India Innovation Fund Direct-Growth 
ITI Bharat Consumption Fund Direct-Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
NJ ELSS Tax Saver Scheme Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth 
Motilal Oswal Nifty 500 Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Groww Nifty Total Market Index Fund Direct - Growth About Metropolis Healthcare
Metropolis Healthcare Limited is an Indian diagnostic services company operating across India and Africa. Founded in 1980 as a pathology partnership, it has evolved into a public company offering a wide range of clinical laboratory tests and profiles. The company operates through a hub and spoke model with 115 clinical laboratories, including a global reference laboratory in Mumbai, regional reference laboratories, satellite laboratories, and express laboratories. Metropolis provides services to both B2B and B2C markets, covering 197 cities in India and has operations in several African countries. The company offers approximately 3,487 clinical laboratory tests and 530 profiles, and has expanded its network through acquisitions and mergers. Metropolis is known for its quality diagnostics and has received awards for customer service and healthcare excellence.
Listing Date
15 Apr, 2019(6 Years,
-10 days)
Chairperson NameAmeera Sushil Shah
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
